Ken Kok
PhD candidate/ guest
- Name
- K. Kok MSc
- Telephone
- +31 71 527 3575
- k.kok@lic.leidenuniv.nl
PhD candidate/ guest
- Science
- Leiden Institute of Chemistry
- LIC/Chemical Biology
- LIC/CB/Medical Biochemistry
- Dam D., Lagerweij N.R., Janmaat K.M., Kok K., Bouwman E. & Codee J.D.C. (2024), Organic dye-sensitized nitrene generation: intermolecular aziridination of unactivated alkenes, Journal of Organic Chemistry (JOC) 89(5): 3251-3258.
- Males A., Kok K., Nin-Hill A., Koster N. de, Beukel S. van den, Beenakker T.J.M., Marel G.A. van der, Codée J.D.C., Aerts J.M.F.G., Overkleeft H.S., Rovira C., Davies G. & Artola Perez de Azanza M.E. (2023), Trans-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump–hole strategy, Chemical Science 14(46): 13581-13586.
- Kok K., Kuo C.L., Katzy R.E., Lelieveld L.T., Wu L., Roig-Zamboni V., Marel G.A. van der, Codee J.D.C., Sulzenbacher G., Davies G.J., Overkleeft H.S., Aerts J.M.F.G. & Artola Perez de Azanza M.E. (2022), 1,6-epi-Cyclophellitol cyclosulfamidate is a bona fide lysosomal α-glucosidase stabilizer for the treatment of Pompe disease, Journal of the American Chemical Society 144(32): 14819-14827.
- Kok K., Zwiers K.C., Boot R.G., Overkleeft H.S., Aerts J.M.F.G. & Artola M. (2021), Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions, Biomolecules 11(2): 271.
- -
- -
- -
- -
- -